Teva Pharmaceutical Industries Ltd.

<div class="infobox">
<div class="infobox-header">Teva Pharmaceutical Industries Ltd.</div>
<div class="infobox-content">
<table>
<tr><th>Stock Symbol</th><td>NYSE: TEVA</td></tr>
<tr><th>Headquarters</th><td>Petah Tikva, Israel</td></tr>
<tr><th>Founded</th><td>1901</td></tr>
<tr><th>Market Cap</th><td>~$20 billion (2026)</td></tr>
<tr><th>2025 Revenue</th><td>$16 billion</td></tr>
<tr><th>Employees</th><td>~40,000</td></tr>
<tr><th>Focus Areas</th><td>Generic pharmaceuticals, CNS/neuroscience, specialty medicines</td></tr>
</table>
</div>
</div>

Overview

<div class="infobox">
<div class="infobox-header">Teva Pharmaceutical Industries Ltd.</div>
<div class="infobox-content">
<table>
<tr><th>Stock Symbol</th><td>NYSE: TEVA</td></tr>
<tr><th>Headquarters</th><td>Petah Tikva, Israel</td></tr>
<tr><th>Founded</th><td>1901</td></tr>
<tr><th>Market Cap</th><td>~$20 billion (2026)</td></tr>
<tr><th>2025 Revenue</th><td>$16 billion</td></tr>
<tr><th>Employees</th><td>~40,000</td></tr>
<tr><th>Focus Areas</th><td>Generic pharmaceuticals, CNS/neuroscience, specialty medicines</td></tr>
</table>
</div>
</div>

Overview

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is an Israeli-American multinational pharmaceutical company headquartered in Petah Tikva, Israel, with operations spanning the United States, Europe, and markets worldwide. Founded in 1901 as a small wholesale drug business in Jerusalem, Teva has grown to become one of the world's largest generic pharmaceutical companies and a significant player in the specialty medicine space, particularly in the central nervous system (CNS) and neuroscience domains["@teva"].

Teva's dual business model combines its leadership position in generic pharmaceuticals with an expanding portfolio of specialty medicines targeting neurological and neurodegenerative diseases. The company has developed significant expertise in treating [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), [Huntington's disease](/diseases/huntingtons), and other CNS conditions. This dual focus provides Teva with both a stable revenue base through generic medications and growth opportunities through innovative therapies["@teva_pipeline"].

The company's neuroscience portfolio includes both approved products and a robust pipeline of investigational therapies targeting movement disorders, neurodegenerative diseases, and conditions affecting the central nervous system. Teva's commitment to neuroscience research reflects both the significant unmet medical need in these areas and the commercial opportunity presented by aging populations worldwide["@pd_epidemiology"][@ad_epidemiology].

Corporate History and Evolution

Founding and Early Growth (1901-1970s)

Teva's origins trace back to 1901 when it was established as a small wholesale drug business in Jerusalem, then part of the Ottoman Empire. The company initially focused on importing and distributing pharmaceuticals in what was then Palestine. The name "Teva" reflects the company's original identity as a manufacturer of medicinal substances derived from plants and natural products.

Throughout the early decades, Teva grew alongside the development of the Israeli pharmaceutical market. The company began manufacturing its own products in the 1930s and 1940s, establishing local production capabilities that would later support broader expansion. The establishment of the State of Israel in 1948 created significant opportunities for domestic pharmaceutical production, and Teva positioned itself as a key supplier to the new country's healthcare system.

Global Expansion (1980s-2000s)

The 1980s marked Teva's emergence as a global pharmaceutical player. The company's 1987 New York Stock Exchange listing provided access to international capital markets and validated its position as a major pharmaceutical company. This period saw Teva begin aggressive expansion beyond Israel, establishing operations in Europe and North America.

The 2000s brought transformative acquisitions that solidified Teva's position as the world's leading generic pharmaceutical company. The 2008 acquisition of Barr Pharmaceuticals gave Teva a significant presence in the U.S. generic market. The 2010 acquisition of Ratiopharm expanded Teva's European generic business. Most significantly, the 2016 acquisition of Allergan's generic business (Actavis) created the largest generic pharmaceutical company in the world by revenue[@teva_acquisitions].

Modern Era (2010s-Present)

In recent years, Teva has navigated significant challenges including patent expirations on specialty products and pricing pressures in the generic industry. The company has responded by focusing on higher-margin specialty products, particularly in CNS and oncology, while maintaining its leadership position in generics. The development of innovative therapies for neurodegenerative diseases has become a strategic priority.

Business Structure and Operations

Generic Pharmaceuticals Division

Teva's generic pharmaceuticals division remains the core of its business, providing high-quality, affordable medications across a wide range of therapeutic areas. The division offers:

Generic Product Portfolio:

• Over 3,500 generic products across multiple dosage forms
• Coverage of nearly all major therapeutic categories
• Generic versions of complex specialty pharmaceuticals

• 70 manufacturing facilities across 20 countries
• Sophisticated manufacturing capabilities including sterile production
• Global supply chain ensuring product availability

• #1 generic pharmaceutical company worldwide by revenue
• #1 in the United States by prescription volume
• Significant presence in European and emerging markets

Specialty Medicine Division

The specialty medicine division focuses on innovative therapies in areas of high unmet medical need, with particular emphasis on CNS disorders. This division includes:

Approved Specialty Products:

• Central nervous system medications
• Respiratory medications
• Biopharmaceuticals and biologics

• Late-stage clinical programs in CNS
• Early-stage research in neurodegenerative diseases
• Partnership programs with biotechnology companies

Neuroscience Portfolio

Approved CNS Products

Teva's approved CNS products address significant unmet needs in movement disorders and neurodegenerative diseases[@vmat2_mechanism][@maob_inhibitors]:

| Product | Generic Name | Indication | Mechanism | Approval Year |
|---------|--------------|------------|-----------|---------------|
| Austedo | Deutetrabenazine | Huntington's disease chorea | VMAT2 inhibitor | 2017 |
| Azilect | Rasagiline | Parkinson's disease | MAO-B inhibitor | 2006 |
| Copaxone | Glatiramer acetate | Multiple sclerosis | Immunomodulator | 1996 |

Austedo (Deutetrabenazine)

Austedo represents Teva's flagship CNS specialty product and one of the company's most significant innovative drug launches. Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of chorea associated with Huntington's disease[@austedo_approval][@hd_chorea].

Mechanism of Action:
VMAT2 inhibitors work by depleting presynaptic dopamine stores, thereby reducing hyperkinetic movements. Deutetrabenazine is a deuterium-containing analog of tetrabenazine, designed to provide improved pharmacokinetic properties including longer half-life and more stable plasma concentrations. The deuterium substitution reduces the rate of metabolism, allowing for twice-daily dosing with reduced peak-to-trough fluctuations[@vmat2_mechanism].

Clinical Efficacy:
The clinical development program for deutetrabenazine included the First-HD (First Huntington's Disease) and ARC-HD (Assessment of Rasagiline in Chorea-Huntington's Disease) trials, demonstrating significant reduction in chorea scores (Unified Huntington's Disease Rating Scale - Total Maximal Chorea) compared to placebo[@deutetrabenazine_arc]. Patients receiving Austedo showed improvement in functional capabilities and quality of life measures.

Market Position:
Austedo has become the standard of care for Huntington's disease chorea and represents a significant commercial success for Teva. The product has generated billions in revenue since launch and continues to grow as awareness of Huntington's disease increases.

Azilect (Rasagiline)

Azilect is a monoamine oxidase B (MAO-B) inhibitor approved as a monotherapy for the treatment of Parkinson's disease symptoms and as an adjunct therapy with levodopa. The product represents Teva's entry into the Parkinson's disease market and has become a widely prescribed medication globally[@azilect_parkinson][@parkinson_neuroprotection].

Mechanism of Action:
Rasagiline works by irreversibly inhibiting MAO-B, the enzyme responsible for metabolizing dopamine in the brain. By reducing dopamine breakdown, the medication increases dopaminergic neurotransmission, improving motor function in Parkinson's disease patients. The irreversible binding means that enzyme activity recovers only with new enzyme synthesis, providing sustained effect with once-daily dosing[@maob_inhibitors].

Clinical Benefits and Disease Modification:
Clinical studies demonstrated that rasagiline provides significant improvement in motor function (measured by MDS-UPDRS scores) both as monotherapy in early disease and as adjunct therapy in patients with motor fluctuations. The TEMPO (TVP-1012 in Early Monotherapy for Parkinson's Disease Outpatients) and ADAGIO (Attenuation of Disease Evolution with Azilect) trials established efficacy and demonstrated disease-modifying potential in early Parkinson's disease[@rasagiline_tempo][@azilect_adagio].

The TEMPO trial showed that rasagiline 1 mg and 2 mg daily provided significant improvement in motor function compared to placebo in patients with early Parkinson's disease who were not receiving dopaminergic therapy. The ADAGIO trial confirmed these findings and demonstrated that early intervention with rasagiline may slow disease progression.

Copaxone (Glatiramer Acetate)

Copaxone is an immunomodulatory medication approved for the treatment of multiple sclerosis. While not directly a neurodegenerative disease therapy, Copaxone represents Teva's extensive neuroscience experience and demonstrates the company's capabilities in CNS drug development[@copaxone_ms].

Mechanism:
Glatiramer acetate is a mixture of random polymers composed of four amino acids that share structural similarity with myelin basic protein. The medication is believed to act by shifting T-cell response from pro-inflammatory (Th1) to anti-inflammatory (Th2) profiles, thereby reducing immune-mediated demyelination.

Pipeline Programs

Teva maintains a significant pipeline of CNS development programs targeting neurodegenerative diseases[@parkinson_neuroprotection][@ad_amyloid_therapy]:

| Program | Indication | Development Stage | Mechanism/Target |
|---------|------------|-------------------|------------------|
| TV-45070 | Parkinson's disease | Phase 2 | Sodium channel blocker |
| Tev-4806 | ALS | Phase 1 | SOD1 inhibitor |
| TEV-56250 | Alzheimer's disease | Preclinical | Amyloid targeting |
| TV-44680 | Parkinson's disease | Phase 1 | Novel target |
| TEV-74750 | Multiple sclerosis | Preclinical | Novel immunomodulator |

TV-45070: Sodium Channel Blocker for Parkinson's Disease

TV-45070 represents Teva's most advanced Parkinson's disease pipeline program. This small molecule targets voltage-gated sodium channels, a novel mechanism for PD treatment[@sodium_channel_pd].

Scientific Rationale:
Sodium channels play a critical role in neuronal excitability and in the pathophysiology of Parkinson's disease. Research has demonstrated that sodium channel blockade can reduce neuronal firing patterns associated with movement disorders and may provide benefit beyond dopaminergic approaches. The Nav1.7 and Nav1.8 sodium channels have been implicated in motor complications of PD, and their modulation may address both motor symptoms and dyskinesias[@sodium_channel_pd].

Development Status:
The Phase 2 program has completed enrollment, evaluating safety and efficacy in Parkinson's disease patients with motor complications. Results from this study will inform further development decisions.

Tev-4806: SOD1 Inhibitor for ALS

Tev-4806 is an investigational therapy targeting superoxide dismutase 1 (SOD1) mutations in amyotrophic lateral sclerosis (ALS)[@als_sod1].

Genetic Rationale:
Approximately 12-20% of familial ALS cases and 1-2% of sporadic ALS cases are caused by mutations in the SOD1 gene. These mutations lead to toxic gain-of-function that causes motor neuron degeneration. Targeting the mutant SOD1 protein represents a precision medicine approach to ALS treatment[@als_sod1].

Mechanism:
Tev-4806 is designed to reduce expression of mutant SOD1 protein through antisense oligonucleotide or small molecule approaches, addressing the underlying genetic cause of disease in SOD1 mutation carriers.

Development Status:
Phase 1 studies are evaluating safety and tolerability in healthy volunteers and ALS patients with SOD1 mutations.

TEV-56250: Alzheimer's Disease Program

TEV-56250 represents Teva's entry into Alzheimer's disease therapeutic development, targeting amyloid pathophysiology[@ad_amyloid_therapy].

Amyloid Hypothesis Context:
The amyloid cascade hypothesis remains a dominant framework for AD therapeutic development. Following the successful FDA approvals of lecanemab (Leqembi) and donanemab, amyloid-targeting approaches have demonstrated clinical benefit in early AD patients. TEV-56250 builds on this foundation with a novel approach to amyloid clearance[@ad_amyloid_therapy].

Development Strategy:
TEV-56250 is in preclinical development, with IND-enabling studies underway. The program leverages Teva's experience in CNS drug development and amyloid biology.

Research Focus and Innovation

Neurodegenerative Disease Research

Teva's neuroscience research focuses on several key areas that represent significant unmet medical needs[@neuroinflammation_target][@protein_degradation_therapy]:

Disease Modification:
Beyond symptomatic treatment, Teva is developing therapies that can slow or halt disease progression. This includes targeting underlying pathological processes including protein aggregation, neuroinflammation, and neuronal dysfunction[@parkinson_neuroprotection].

Novel Drug Delivery:
Teva invests in advanced drug delivery technologies that can improve CNS drug distribution. This includes novel formulations, delivery systems, and approaches to overcome blood-brain barrier limitations[@cns_drug_delivery].

Targeted Protein Degradation:
Emerging protein degradation technologies, including PROTACs and molecular glues, offer new approaches to previously "undruggable" targets. Teva is exploring these modalities for neurodegenerative disease applications[@protein_degradation_therapy].

Neuroinflammation Modulation

Neuroinflammation has emerged as a key contributor to neurodegenerative disease progression. Teva's research programs include:

• Microglial modulation strategies
• Cytokine pathway inhibitors
• Astrocyte-targeted approaches

Dopaminergic and Serotonergic Therapies

Teva's extensive experience in movement disorders extends to understanding dopaminergic and serotonergic neurotransmission[@neurotransmitter_therapy]:

Dopaminergic Approaches:

• MAO-B inhibitors (rasagiline)
• [Dopamine agonists](/therapeutics/dopamine-agonists)
• Levodopa combinations

• 5-HT2A antagonists for dyskinesia
• Serotonergic-dopaminergic interactions

Generic Neurology Portfolio

Teva's generic portfolio provides affordable access to essential neurological medications worldwide. The company produces generic versions of major neurological therapies:

Movement Disorder Medications:

• [Levodopa](/therapeutics/levodopa)/Carbidopa combinations (generic Sinemet)
• Pramipexole (generic Mirapex)
• Ropinirole (generic Requip)
• Selegiline and rasagiline

• Gabapentin
• Pregabalin
• Lamotrigine
• Topiramate

• Modafinil (wakefulness-promoting)
• Clonazepam
• Lorazepam

Global Market Position

Pharmaceutical Industry Context

Teva operates in the context of significant industry dynamics:

Generic Market Trends:

• Increasing pressure on generic pricing globally
• Consolidation among generic manufacturers
• Value-added generic products and specialty generics
• Biosimilar market growth and opportunity

• Growing neurodegenerative disease prevalence globally[@pd_epidemiology]
• Unmet needs in disease-modifying therapies
• Aging populations driving demand
• Innovation in novel therapeutic modalities

Competitive Position

Teva maintains competitive advantages through:

Scale:

• Largest generic pharmaceutical company by revenue
• Global manufacturing and distribution network
• Significant bargaining power with suppliers

• Dual generic/specialty business model
• Broad therapeutic portfolio
• Geographic diversification

• Established CNS pipeline
• Research capabilities in neurodegeneration
• Partnership capabilities

Sustainability and Corporate Responsibility

Teva has increasingly focused on sustainability and corporate responsibility in its operations:

Environmental Initiatives:

• Carbon footprint reduction programs
• Water conservation in manufacturing
• Waste reduction and recycling programs

• Generic drug programs for underserved populations
• Patient assistance programs
• Global health partnerships

• Board oversight of environmental and social issues
• Transparent reporting on sustainability metrics
• Ethical business practices

Strategic Outlook

Growth Drivers

Teva's future growth is expected to be driven by:

Challenges

Teva faces several challenges:

Strategic Priorities

Teva's strategic priorities include:

• Maximize Austedo potential: Continued growth in Huntington's disease market
• Advance CNS pipeline: Progress TV-45070, Tev-4806, and TEV-56250
• Strengthen generics position: Optimize portfolio and maintain market leadership
• Explore external innovation: Partnerships and acquisitions to augment internal capabilities

Impact on Neurodegenerative Disease Care

Teva contributes significantly to neurodegenerative disease care through multiple pathways:

Treatment Access:

• Affordable generic medications for Parkinson's disease, multiple sclerosis
• Specialty products like Austedo addressing unmet needs
• Global distribution ensuring medication availability

• Disease-modifying therapy development
• Novel mechanisms beyond dopaminergic approaches
• Focus on high-unmet-need conditions

• Clinical trial programs advancing neuroscience
• Real-world evidence generation
• Academic and industry collaborations

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Huntington's Disease](/diseases/huntingtons)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [VMAT2 Inhibitors](/therapeutics/vmat2-inhibitors)
• [MAO-B Inhibitors](/therapeutics/mao-b-inhibitors)
• [Generic Pharmaceuticals](/companies/generic-pharmaceuticals)
• [CNS Drug Development](/companies/ad-pipeline-companies)

External Links

• [Teva Pharmaceutical Industries](https://www.tevapharm.com/)
• [Teva Pipeline](https://www.tevapharm.com/pipeline/)
• [Austedo Patient Information](https://www.austedo.com/)
• [Azilect Prescribing Information](https://www.azilect.com/)

References

<!-- expansion-work-done-2026-03-27 -->